Introduction
The Cat CD279/PDCD1/PD1 HEK293T Stable Cell Line is a valuable tool for studying the role of the programmed cell death protein 1 (PD-1) in immune response and cancer therapy. This stable cell line is derived from human embryonic kidney cells (HEK293T) and expresses the feline homolog of PD-1, also known as CD279 or PDCD1. In this article, we will provide a scientific description of the structure, activity, and application of this cell line, with a focus on its use as a therapeutic target in cancer treatment.
Structure of Cat CD279/PDCD1/PD1 HEK293T Stable Cell Line
The Cat CD279/PDCD1/PD1 HEK293T Stable Cell Line is a genetically modified cell line that stably expresses the feline PD-1 protein. The PD-1 protein is a transmembrane receptor that belongs to the immunoglobulin superfamily. It consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain contains an immunoglobulin variable domain and an immunoglobulin constant domain, which are responsible for binding to its ligands, PD-L1 and PD-L2. The intracellular domain contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM), which are crucial for the inhibitory function of PD-1.
Activity of Cat CD279/PDCD1/PD1 HEK293T Stable Cell Line
The Cat CD279/PDCD1/PD1 HEK293T Stable Cell Line is a powerful tool for studying the activity of PD-1 in immune response and cancer. PD-1 is a key immune checkpoint that plays a critical role in maintaining immune homeostasis and preventing autoimmunity. When PD-1 binds to its ligands, PD-L1 and PD-L2, it inhibits T cell activation and promotes immune tolerance. This mechanism is important for preventing excessive immune response and tissue damage. However, cancer cells can exploit this mechanism to evade immune surveillance and promote tumor growth. Therefore, targeting PD-1 has emerged as a promising strategy for cancer immunotherapy.
The Cat CD279/PDCD1/PD1 HEK293T Stable Cell Line can be used to study the interaction between PD-1 and its ligands, as well as the downstream signaling pathways that mediate its inhibitory function. This cell line can also be used to screen for potential PD-1 inhibitors or agonists, which can be further developed as therapeutic agents for cancer treatment.
Application of Cat CD279/PDCD1/PD1 HEK293T Stable Cell Line
The Cat CD279/PDCD1/PD1 HEK293T Stable Cell Line has a wide range of applications in both basic research and drug discovery. In basic research, this cell line can be used to investigate the role of PD-1 in immune response and cancer progression. It can also be used to study the mechanisms of action of existing PD-1 inhibitors and identify potential therapeutic targets for cancer treatment.
In drug discovery, the Cat CD279/PDCD1/PD1 HEK293T Stable Cell Line can be used to screen for novel PD-1 inhibitors or agonists. These compounds can then be further tested in animal models and clinical trials for their efficacy and safety in cancer treatment. This cell line can also be used to evaluate the efficacy of combination therapies, where PD-1 inhibitors are used in combination with other cancer treatments, such as chemotherapy or radiation therapy.
Flow Cytometry Analysis of Cat CD279/PDCD1/PD1 HEK293T Stable Cell Line
Flow cytometry is a powerful technique for analyzing the expression of cell surface proteins, such as PD-1.
There are no reviews yet.